CVC Capital Partners will raise HK$620 million ($80 million) through a block trade of shares in Jintian Pharmaceutical Group, a Chinese pharmaceutical retailer and distributor.
Greater China | 08 Oct 2014 |
When John Thomson, head of 3i Group’s Southeast Asia business, met Singaporean entrepreneur Jay Pok in the mid-2000s, he was on the lookout for a medical technology investment. But Pok’s company, medical cable maker LHi Technology, though impressive,...
Exits | 08 Oct 2014 |
A consortium of investors including Archer Capital is subject to a civil action launched by New Zealand’s Financial Markets Authority (FMA) over an unsuccessful bid for Abano Healthcare Group.
Regulation | 06 Oct 2014 |
3i Group has exited LHi Technology – a medical equipment manufacturer bought from Baring Private Equity Asia in 2008 – to US-based Carlisle Companies for an enterprise valuation of around $195 million, claiming a 2.9x money multiple.
Exits | 03 Oct 2014 |
SPi Global, a Philippines-based business process outsourcing (BPO) provider owned by CVC Capital Partners, has agreed to sell its US healthcare business to Conifer Health Solutions in a deal worth $235 million.
Exits | 26 Sep 2014 |
Spring Seeds Capital, an investment arm of government-backed Spring Singapore, has launched an initiative that could channel up to S$60 million ($47 million) into local medical technology start-ups.
Southeast Asia | 26 Sep 2014 |
Driven by an aging population, increasing health awareness and a rising middle class, China's medical device market is growing at a rapid pace. A recent report by the Hong Kong Medical and Healthcare Device Industries Association reveals that since 2000...
Healthcare | 24 Sep 2014 |
The Blackstone Group has picked up a significant stake in Chinese medical devices company Xinrong Best Medical Instrument. Financial details were not disclosed but the deal is understood to be worth around $100 million.
Greater China | 23 Sep 2014 |
India Vaue Fund Advisors (IVFA) has bought a 10% stake in Syngene International, the research unit of Indian bio-pharmaceuticals firm Biocon, for INR3.8 billion ($62 million).
South Asia | 19 Sep 2014 |
Xiaomi Ventures, a corporate VC unit of Chinese mobile phone maker Xiaomi, has paid $25 million for a 20% stake in iHealth, an offshore unit of healthcare electronics maker Andon Health.
Greater China | 19 Sep 2014 |
Few VC firms are keen to invest in China's early-stage drug discovery space because the development cycle is long and risky. Taking a new drug from clinical testing to commercialization often takes 7-10 years and the success rate in China is less than...
Healthcare | 11 Sep 2014 |
Zhongyuan Union Stem Cell Bio-engineering, a Chinese stem cell storage service operator, has partnered with China Yinhong Capital to launch an industry M&A fund with a target of RMB5 billion ($813 million).
Greater China | 03 Sep 2014 |
OrbiMed has committed $15 million in Series B funding to GC-Rise Pharmaceutical, a Chinese healthcare services provider.
Healthcare | 03 Sep 2014 |
Tencent Holdings has invested $70 million into dxy.com, a Chinese networking and information-sharing site for healthcare professionals
Venture | 03 Sep 2014 |
Updating your subscription status
In 2015, China is expected to experience a "new normal of growth". For private equity investors, China's new stage of growth represents huge opportunities: an increase of 270% in online consumption, the reform of over a hundred sovereign-owned enterprises, trillion-dollar investments into overseas infrastructure projects, the rising entrance of young entrepreneurs, and many more.
To be held on 28 and 29 May, the 14th annual AVCJ China Forum 2015 in Beijing will feature these exciting topics and bring together top-notch speakers from across the world.Join the premium industrial gathering of over 300 private equity professionals, regulators and senior executives for two days of mind-provoking discussions, networking and more.
28-29 May 2015, China World Summit Wing,Beijing
There is a feeling that now is a shrewd time to invest in Japan and take advantage of the favourable conditions for private equity. Valuations are low compared with the rest of Asia and strategic buyers and the IPO market are providing an attractive route for exits. There are also signs that corporate Japan is slowly coming around to engaging PE as a potential buyer for non-core assets and recent developments at the GPIF suggest that PE will be under strong consideration for allocations from pension funds in the near future as well as regional banks committing to the asset class right now.
The macro concerns that have been present for many years still remain in terms of low growth and currency depreciation but these are encouraging times for fund managers looking to both raise capital from Japanese LPs and make investments.
245-26 June 2015, Conrad Hotel, Tokyo